SavedAdd your journal

Journals / Türk Kardiyoloji Derneği Arşivi / 2018 / Cilt: 46 - Sayı: 6

Association between SYNTAX II score and electrocardiographic evidence of no-reflow in patients with ST-segment elevation myocardial infarction

ST-segment yükselmeli miyokart enfarktüsü bulunan hastalarda SYNTAX Skoru II ile elektrokardiyografik no-reflow arasındaki ilişki

Erdal Aktürk
Lütfü Aşkın
Pages
455–463
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

MACE is a composite endpoint frequently usedin cardiovascular research and usually includes endpoints reflectingsafety and effectiveness. ΣSTR

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study was performed to examine the associationbetween the SYNTAX II score (SS-II) and no-reflowobserved on electrocardiography and examine their use inthe evaluation of risk of an in-hospital major adverse cardiovascularevent (MACE) in patients with ST-segment elevationmyocardial infarction (STEMI).Methods: A total of 126 consecutive STEMI patients who underwentprimary percutaneous coronary intervention (pPCI)were recruited.
📊
Key Findings & Data:The difference in the sum of STsegmentelevations measured between before the pPCI andthe assessment determined approximately 60 minutes afterthe pPCI was interpreted as the sum of ST-segment resolution(ΣSTR).
💡
Conclusion & Impact:MACE is a composite endpoint frequently usedin cardiovascular research and usually includes endpoints reflectingsafety and effectiveness. ΣSTR
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: This study was performed to examine the associationbetween the SYNTAX II score (SS-II) and no-reflowobserved on electrocardiography and examine their use inthe evaluation of risk of an in-hospital major adverse cardiovascularevent (MACE) in patients with ST-segment elevationmyocardial infarction (STEMI).Methods: A total of 126 consecutive STEMI patients who underwentprimary percutaneous coronary intervention (pPCI)were recruited. The SS-II was derived using angiographic andbasic patient clinical features. The difference in the sum of STsegmentelevations measured between before the pPCI andthe assessment determined approximately 60 minutes afterthe pPCI was interpreted as the sum of ST-segment resolution(ΣSTR). MACE is a composite endpoint frequently usedin cardiovascular research and usually includes endpoints reflectingsafety and effectiveness. ΣSTR

Özet

Amaç: Bu çalışma, ST-segment yükselmeli miyokart enfarktüsü (STEMİ) bulunan hastalarda SYNTAX skoru II (SS-II) ile elektrokardiyografide no-reflow arasındaki ilişkiyi ve iki skorun hastane içi ciddi istenmeyen kardiyovasküler olayların (MACE) belirlenmesinde doğruluğunun incelenmesi amacıyla yapıldı. Yöntemler: Bu çalışmaya primer perkütan koroner girişim (pPCI) uygulanmış toplam 126 ardışık STEMİ’li hasta alındı. SS-II anjiyografik ve temel hasta klinik özellikleri kullanılarak elde edildi. PPCİ’den önce ölçülen ve pPCİ sonrası yaklaşık 60 dakika sonra saptanan ST segment yüksekliklerinin toplamındaki fark ST-segment çözünürlüğü (ΣSTR) toplamı olarak yorumlanmıştır. MACE, kardiyovasküler araştırmalarda sıklıkla kullanılan bir kompozit son noktadır ve genellikle güvenilirliği ve etkinliği yansıtan uç noktaları içerir. ΣSTR

🔖

Cite This Article

Aktürk, E., Aşkın, L. (2022). Association between SYNTAX II score and electrocardiographic evidence of no-reflow in patients with ST-segment elevation myocardial infarction. Türk Kardiyoloji Derneği Arşivi, Cilt: 46 - Sayı: 6, 455–463. https://ajindex.com/articles/632133

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Acet H, Ertaş F, Bilik MZ, Aydın M, Yüksel M, Polat N, Yıldız A, et al. The relationship of TIMI risk index with SYNTAX and Gensini risk scores in predicting the extent and severity of coronary artery disease in patients with STEMI undergoing primary percutaneous coronary intervention. Ther Adv Cardiovasc Dis 2015;9:257–66
  2. Farooq V, van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo A, et al. Anatomical and clinical characdevelopment teristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet 2013;381:639–50
  3. Xu B, Généreux P, Yang Y, Leon MB, Xu L, Qiao S, et al. Validation and comparison of the long-term prognostic capability of the SYNTAX score-II among 1,528 consecutive patients who underwent left main percutaneous coronary intervention. JACC Cardiovasc Interv 2014;7:1128–37
  4. Morishima I, Sone T, Mokuno S, Taga S, Shimauchi A, Oki Y, et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J 1995;130:239–43
  5. Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, et al. Incidence and treatment of ‘no-reflow’ after percutaneous coronary intervention. Circulation 1994;89:2514–8
  6. Ito H, Okamura A, Iwakura K, Masuyama T, Hori M, Takiuchi S, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996;93:1993–9. 7. van ‘t Hof AW, Liem A, de Boer MJ, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lancet 1997;350:615–9
  7. Reffelmann T, Kloner RA. The “no-reflow” phenomenon: basic science and clinical correlates. Heart 2002;87:162–8
  8. Abdi S, Rafizadeh O, Peighambari M, Basiri H, Bakhshandeh H. Evaluation of the Clinical and Procedural Predictive Factors of no-Reflow Phenomenon Following Primary Percutaneous Coronary Intervention. Res Cardiovasc Med 2015;4:e25414
  9. Schwartz BG, Kloner RA. Coronary no reflow. J Mol Cell Cardiol 2012;52:873–82
  10. Ragosta M, Camarano G, Kaul S, Powers ER, Sarembock IJ, Gimple LW. Microvascular integrity indicates myocellular viability in patients with rec